Kostas from Cyprus

Registered at the short selling broker eToro, 2 minutes ago.

» Try eToro you too
67% of retail investor accounts lose money when trading CFDs with etoro.
Don't show again

Novavax, Inc. (NVAX) shares information

Novavax, Inc.


24h Change

-6.91 %

NVAX

Live rate:

Stock data per Wednesday 5 Oct, 2022

NVAX
NASDAQ
19.4
18.06
-1.34 (-6.91%)
US Market is open

Live Stock price in graph for Novavax, Inc. (NVAX)

Data updated continously for NVAX, showing up to the 500 most recent 100 data points

  • Latest Volume

    1,890,957 (-39.95 %)

  • Volume prev. day

    3,149,173

  • Avg. daily volume

    4,573,336

  • Market cap

    1,411,110,786

  • P/E ratio

    -0.95

  • Today high

    n/a

  • Today low

    n/a

  • 52 week high

    236.5 USD

  • 52 week low

    17.11 USD

  • YTD Change

    n/a

Quick links

 

Latest news about Novavax, Inc.

Below you can find the most recent news posts about Novavax, Inc., primarily from US and UK based news sources.

Omicron subvariant 4.6 continues to account for more COVID cases – CDC (NASDAQ:NVAX)

Wednesday, 5 October 2022, 00:02:26
New data from the CDC shows that BA.4.6, a subvariant of the Omicron variant, is continuing to account for a growing number of COVID-19 cases.For the week ended Oct
— Seeking Alpha


Novavax Inc. (NASDAQ: NVAX): It Is A Stock Worth Considering Today

Monday, 3 October 2022, 15:30:00
In the last trading session, 3.75 million shares of the Novavax Inc. (NASDAQ:NVAX) were traded, and its beta was 1.85. Most recently the company’s share price was $18.20, and it changed around -$0.37 or -1.99% from the last close, which brings the market valuation of the company to $1.45B. NVAX currently trades at a discount … Novavax Inc. (NASDAQ: NVAX): It Is A Stock Worth Considering Today Read More »
— Marketing Sentinel


Codexis Announces Appointment of Rahul Singhvi, Sc.D., to Board of Directors

Monday, 3 October 2022, 14:00:00
REDWOOD CITY, Calif., Oct. 03, 2022 (GLOBE NEWSWIRE) — Codexis, Inc. (NASDAQ: CDXS ), a leading enzyme engineering company enabling the promise of synthetic biology, today announced the appointment of Rahul Singhvi, Sc.D., to its Board of Directors. Dr. Singhvi is a biotechnology industry veteran with more than three decades of research and development, operations and commercialization expertise across his time with Takeda Pharmaceutical Co., Novavax, Inc. and Merck & Co., Inc. He currently serves as the Chief Executive Officer of National Resilience, Inc. (Resilience), a technology-focused biomanufacturing company, which he co-founded and built, with end-to-end manufacturing and digital solutions across several modalities including cell and gene therapies, nucleic acids, vaccines and biologics. “Rahul is a proven leader in the biopharmaceutical industry, with a demonstrated track record of enabling scale and accelerating the growth of innovative product pipelines,” said Byron Dorgan, Chair of the Board of Codexis. “His insights and guidance across drug development and driving adoption of boundary-pushing technologies will prove invaluable throughout Codexis” evolution, and we are fortunate to welcome him to …
— Benzinga


Novavax Stock: Beware This Hypercoaster (NASDAQ:NVAX)

Friday, 30 September 2022, 07:23:41
Novavax is the hypercoaster of stocks having crested $300 in 02/22, falling to <$130 and then doubling and then crashing. See why NVAX is a tricky holding.
— Seeking Alpha


MRNA stock, NVAX stock, OCGN stock plunge (NASDAQ:MRNA)

Thursday, 29 September 2022, 16:47:19
The shares of COVID-19 vaccine makers witnessed a sharp decline on Thursday morning, with Moderna (MRNA) and Novavax (NVAX) reaching 52-week lows.Its rivals in COVID-19 vaccine…
— Seeking Alpha


Trading broker recommendation

We recommend that you check out Capital.com as they have a very good selection of stocks available for both going short and long.

Rating: 9.57/10
Minimum deposit: €250 by bank
Description: Capital.com offer a large number of stocks for trading. Register an account today and check if they have NVAX available or trade one of the many other CFD stocks they have.
Risk warning: 67.7% of retail investor accounts lose money when trading CFDs with Capital.